#USA #New York #Gross Law Firm #Shareholders #Mereo BioPharma

Important Announcement for Mereo BioPharma Shareholders

The Gross Law Firm has issued a crucial notice for shareholders of Mereo BioPharma Group plc (NASDAQ: MREO) regarding an ongoing class action lawsuit. As part of this legal action, shareholders who acquired MREO shares between June 5, 2023, and December 26, 2025, are directed to potentially serve as lead plaintiffs. This information is vital for those affected, as the lead plaintiff designation can play a significant role in the outcome of the case.

Context of the Lawsuit

The lawsuit revolves around allegations against Mereo BioPharma for making misleading statements about its clinical trial programs, specifically the Phase 3 ORBIT and COSMIC studies. The company previously issued optimistic statements regarding these trials, which purportedly failed to meet their endpoints. On December 29, 2025, Mereo disclosed that the studies did not demonstrate statistical significance in reducing the annualized clinical fracture rate compared to control groups, despite some improvements in bone mineral density. This revelation caused Mereo's share price to plummet more than 87% within days, drastically impacting many investors’ portfolios.

Key Dates and Deadlines

Shareholders are encouraged not to delay in taking action regarding this lawsuit. The deadline to file a request for lead plaintiff status is set for April 6, 2026. This timeline provides shareholders a window to register and possibly take the lead in this significant legal proceeding.

Next Steps for Interested Shareholders

If you have purchased Mereo shares within the specified class period, it is crucial that you register your information. Registration will not only keep you informed about the proceedings but also enroll you in monitoring software that provides updates on the case's status throughout its lifecycle.

To register, shareholders can visit the Gross Law Firm's dedicated webpage. Participating in the case as a lead plaintiff does not require any financial cost or obligation.

Why Choose the Gross Law Firm?

The Gross Law Firm has established itself as a reputable class action law firm with a commitment to protecting investors' rights. Their focus on addressing issues of fraud and corporate misconduct has earned them national recognition. They are dedicated to ensuring that companies are held accountable for misleading practices that result in investor losses.

If you wish to learn more about this case or require further assistance, do not hesitate to reach out to them directly via their contact details provided.

Contact Information

• - The Gross Law Firm

15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

This announcement highlights the importance of active participation from shareholders, ensuring they have a voice in the proceedings against Mereo BioPharma. As deadlines approach, interested parties should act promptly to safeguard their interests.